In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4407-11. doi: 10.1128/AAC.00627-16. Print 2016 Jul.

Abstract

Lefamulin was evaluated against various Streptococcus pneumoniae serotypes that were collected from adults with lower respiratory tract infections. Lefamulin exhibited MIC50 and MIC90 values of 0.12 and 0.25 μg/ml, respectively, against the entire collection (n = 822). Similar results were obtained for lefamulin against each of the most common serotypes as well as against multidrug-resistant isolates and strains that are nonsusceptible to ceftriaxone or erythromycin. These data support the clinical development of lefamulin for the treatment of community-acquired respiratory tract infections.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Cephalosporins / pharmacology*
  • Drug Resistance, Multiple, Bacterial
  • Erythromycin / pharmacology*
  • Microbial Sensitivity Tests
  • Respiratory Tract Infections / microbiology*
  • Serogroup
  • Streptococcus pneumoniae / drug effects*
  • United States

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • Erythromycin

Grants and funding

This study and manuscript preparation were sponsored by an educational/research grant from Nabriva Therapeutics AG (Vienna, Austria) via the SENTRY Antimicrobial Surveillance Program platform.